Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Afatinib impurity 3 is a quantified impurity of Afatinib, a selective irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. This compound is primarily utilized in the evaluation of drug purity and quality control in pharmaceutical research and development. Its characterization is essential for compliance with regulatory standards and for ensuring the safety and efficacy of Afatinib-based therapies. -
Drug Impurity
Apixaban impurity 11 is a known impurity associated with the anticoagulant Apixaban. This compound is essential for the characterization of Apixaban in pharmaceutical formulations and stability studies. Its presence and quantification are important in ensuring the quality and efficacy of the drug during development and production processes. -
Drug Impurity
Ropinirole impurity 12 is a chemical impurity associated with the analgesic and anti-Parkinson agent, Ropinirole. This compound plays a critical role in the assessment of drug purity and stability, as it can potentially affect the pharmacological profile of the parent compound. Additionally, Ropinirole impurity 12 is useful in research focused on formulation development, quality control, and compliance with regulatory standards for pharmaceutical products. -
Drug Impurity
Indobufen Impurity 6 is a structural impurity associated with Indobufen. It serves as a valuable reference standard for analytical and quality control applications in pharmaceutical research. The characterization of this impurity can aid in assessing the purity and stability of Indobufen formulations, contributing to the understanding of its pharmacological properties. -
Drug Impurity
Terbinafine impurity 1 hydrochloride is a known impurity of the antifungal agent terbinafine hydrochloride. This compound is important for analytical studies focused on drug purity, stability, and formulation development. Researchers can use it to validate analytical methods and ensure compliance with regulatory standards in pharmaceutical testing. -
Drug Impurity
Metoprolol impurity 10 is a characterized impurity of the beta-blocker Metoprolol, primarily affecting the drug's purity assessment and quality control. Its analysis is essential in pharmaceutical research to ensure compliance with regulatory standards. This compound serves as a reference for detecting and quantifying impurities in formulation studies and stability assessments of Metoprolol. -
Drug Impurity
Dronedarone impurity 25 hydrochloride is a designated impurity associated with the antiarrhythmic drug Dronedarone. It serves as a crucial reference standard in the analysis and quality control of Dronedarone, facilitating the evaluation of drug purity and stability. This compound is significant for researchers and pharmaceutical developers engaged in the synthesis, development, and regulatory assessment of cardiovascular therapeutics. -
Drug Impurity
Sitagliptin impurity 29 is a known impurity of the DPP-4 inhibitor Sitagliptin. Its identification and characterization are crucial for assessing the purity of Sitagliptin during drug development and quality control processes. This compound is important for researchers investigating the safety, efficacy, and regulatory compliance of Sitagliptin formulations. -
Drug Impurity
Posaconazole impurity 4 is a characterized impurity of the antifungal agent Posaconazole. It serves as a reference standard for analytical studies and quality control processes in pharmaceutical research. The identification and quantification of this impurity are essential for ensuring the purity and efficacy of Posaconazole formulations in clinical settings. -
Drug Impurity
Sofosbuvir impurity 3 is a characterized impurity of the antiviral agent Sofosbuvir, primarily targeting hepatitis C virus replication. This compound serves as a vital reference standard in the analytical evaluation of Sofosbuvir formulations, ensuring the quality and safety of therapeutic applications. Its assessment is crucial for researchers conducting studies on drug metabolism, stability, and impurity profiling in pharmaceutical development. -
Drug Impurity
Brimonidine impurity 7, also known as 6-Quinoxalinamine, is a chemical impurity associated with the synthesis of Brimonidine. This compound serves as an important reference standard in analytical chemistry for the detection and quantification of impurities in pharmaceutical formulations. Its characterization can aid in understanding the stability and quality of Brimonidine-related products. -
Drug Impurity
Sacubitrilat impurity 34 is a known impurity associated with Sacubitrilat, a vasodilator that inhibits neprilysin, thereby increasing levels of natriuretic peptides. This compound is primarily utilized in drug development and quality control assessments to ensure the purity of Sacubitrilat formulations. Its presence in analytical studies aids in understanding the metabolism and safety profiles of the parent drug. -
Drug Impurity
Dapagliflozin impurity 111 is an impurity associated with the antidiabetic agent Dapagliflozin, which targets sodium-glucose cotransporter 2 (SGLT2). This compound serves as a critical analytical reference for the assessment of drug purity and quality control in pharmaceutical formulations. The study of this impurity is important for understanding the stability and safety profiles of SGLT2 inhibitors in drug development. -
Drug Impurity
Vitamin Impurity 3 is a recognized impurity associated with Vitamin compounds. It may arise during synthesis or degradation processes and is primarily investigated for its potential effects on the stability and efficacy of vitamin formulations. This reagent is essential for quality control and regulatory compliance in pharmaceutical research, allowing scientists to assess the purity of vitamin products and their implications for safety and effectiveness. -
Drug Impurity
4-Chloro-2-methoxybenzonitrile is identified as a drug impurity primarily involved in pharmaceutical applications. Its presence may affect the safety and efficacy of drug formulations, making it a critical compound for analytical chemistry studies. Researchers utilize this reagent to investigate the impact of impurities in drug development and quality control processes. -
Drug Impurity
Ilurodoline impurity 10 is a synthetic impurity associated with the drug Ilurodoline. This compound serves as a valuable reference standard for analytical and quality control applications in the pharmaceutical industry. Its characterization is crucial for ensuring the purity and safety of Ilurodoline in drug formulation and development processes. -
Drug Impurity
Tadalafil impurity 16 is a known impurity of Tadalafil, primarily involved in the assessment of pharmaceutical quality and characterization of drug substances. This compound serves as a critical reference standard for the analysis of Tadalafil formulations, ensuring compliance with regulatory guidelines. Its presence can impact the efficacy and safety profiles of Tadalafil, making it essential for analytical and quality control applications in drug development and manufacturing. -
Drug Impurity
Arolol impurity 2 is a characterized drug impurity associated with Arolol. Due to its presence, it is essential for the assessment of pharmaceutical formulations and quality control processes. This compound is used in research to ensure the purity and safety of drug products, ultimately aiding in the development of therapeutically effective formulations. -
Drug Impurity
Rosuvastatin impurity 52 is a known impurity of the cholesterol-lowering agent Rosuvastatin, primarily affecting its purity profile. This compound is crucial for quality control and analytical studies, aiding in the assessment of synthetic processes and regulatory compliance. It is utilized in pharmaceutical research to ensure the integrity of drug formulations and to evaluate the safety and efficacy of Rosuvastatin. -
Drug Impurity
BOC-Ile-N(OCH3)CH3 is a chemical compound that serves as a drug impurity, specifically an N-derivative of isoleucine. This reagent is pivotal in pharmaceutical development and quality control, as it allows for the analysis of drug formulations and the understanding of synthesis pathways. Its relevance in research extends to evaluating the stability and purity of drug substances. -
Drug Impurity
Uradil Impurity 1 is identified as an impurity of Uradil, primarily serving as a reference standard in drug development and quality control. Its presence may affect the safety and efficacy profiles of pharmaceutical formulations, making it critical for analytical characterization. Research applications include stability testing and impurity profiling to ensure compliance with regulatory standards in drug formulation. -
Drug Impurity
2-Cyanoethyl acetoacetate is a chemical compound that serves as a drug impurity. It is significant in analytical chemistry for assessing the purity of pharmaceutical formulations and studying degradation pathways of drug candidates. Researchers utilize this reagent to investigate the stability and quality control of various therapeutic agents. -
Drug Impurity
Nintedanib impurity 3 is a chemical impurity related to Nintedanib, a receptor tyrosine kinase inhibitor. This compound is significant for analytical and quality control purposes in pharmaceutical research and development. Its identification and quantification are crucial for ensuring the safety and efficacy of Nintedanib formulations. -
Drug Impurity
7-Deazapurine impurity 1 is a known impurity associated with the synthesis of purine derivatives. This compound may arise during the production of specific pharmaceuticals and is critical for assessing the purity and quality of drug formulations. Its analysis is essential in pharmaceutical research and development to ensure compliance with regulatory standards. -
Drug Impurity
Linagliptin impurity 34 is a chemical impurity associated with Linagliptin, a DPP-4 inhibitor. This substance is critical for the assessment of drug purity and quality control in pharmaceutical research. Its characterization and analytical evaluation are essential for understanding the metabolic profile and potential safety implications of Linagliptin formulations. -
Drug Impurity
Tofacitinib impurity 32 is a chemical impurity associated with the kinase inhibitor Tofacitinib. Its characterization is essential for assessing the purity and quality of pharmaceutical formulations. This reagent is utilized in research focused on the development and validation of analytical methods for drug analysis, as well as for stability studies in pharmaceutical sciences. -
Drug Impurity
Timolol impurity 1 is a known impurity of the beta-adrenergic antagonist Timolol. Its characterization is essential for quality control in pharmaceutical development, ensuring the purity and safety of the final drug product. This reagent is useful for analytical studies and method validation in drug formulation and stability testing. -
Drug Impurity
Suvorexant impurity 1 is a by-product of Suvorexant synthesis, primarily associated with drug formulation and quality control. This impurity may be utilized in analytical studies to examine the effects of impurities on potency and efficacy in drug development. Research applications include stability testing and profiling of Suvorexant formulations, contributing to better understanding of safety and pharmacokinetics in preclinical studies. -
5-ASA Impurity
3-Aminosalicylic acid is a key impurity associated with the synthesis of 5-Aminosalicylic acid, a known agonist of PPARγ and an inhibitor of p21-activated kinase 1 (PAK1) and NF-κB. This compound is primarily used in research related to inflammatory bowel diseases such as Crohn's disease and ulcerative proctitis. Its role in modulating these pathways makes it significant for studies focused on therapeutic interventions and drug development in gastrointestinal conditions. -
Drug Impurity
Nintedanib impurity 7 is a known impurity associated with Nintedanib, targeting multiple receptor kinase pathways. It serves as a critical reference standard for assessing the purity of Nintedanib formulations in pharmacokinetic studies and quality control. This compound is valuable for researchers examining drug safety, efficacy, and metabolic pathways related to Nintedanib and its therapeutic applications. -
Drug Impurity
Afatinib impurity 36 is a chemical impurity associated with the drug Afatinib, an irreversible ErbB receptor tyrosine kinase inhibitor. This impurity is utilized in the analytical assessment of Afatinib’s purity and quality, aiding in the development and validation of pharmaceutical formulations. Its identification is essential for maintaining compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Cannabidiol impurity 1 is a known impurity derived from Cannabidiol. This compound is often identified during the analysis and purification processes of Cannabidiol formulations. Its presence can impact the purity and potency of cannabinoid products, making it relevant for quality control and regulatory compliance in pharmaceutical and nutraceutical research. -
Drug Impurity
6,7-Dihydropyrazino[2,3-d]pyridazine-5,8-dione is identified as a drug impurity that may arise during the synthesis of pharmaceutical compounds. Its presence can impact the purity and safety profile of drug formulations. This compound is important for research applications that focus on the characterization and quantification of impurities in drug development and quality control processes. -
Drug Impurity
Butenafine impurity 2 is a drug impurity related to Butenafine, a compound primarily used as an antifungal agent. This impurity can be crucial for analytical studies and quality control in pharmaceutical development. Its characterization helps ensure the safety and efficacy of Butenafine formulations in research and clinical applications. -
Drug Impurity
Atenolol impurity 5 (p-Hydroxy pheny lacetamide) serves as a drug impurity of Atenolol. This compound is significant for analytical chemistry applications, particularly in the quality control and pharmacokinetic studies of Atenolol formulations. It aids in assessing the purity and safety profiles of Atenolol and can be utilized in method development for impurity identification and quantification. -
Drug Impurity
Metoprolol Impurity 42 is a known impurity associated with the beta-blocker Metoprolol. This compound is primarily used for analytical research applications to assess drug purity and stability. Its presence may provide insights into the metabolic pathways and degradation products related to Metoprolol, aiding in quality control and regulatory compliance studies. -
Drug Impurity
Ribociclib Impurity 2 is a known impurity associated with the cyclin-dependent kinase 4 and 6 inhibitor Ribociclib. This compound is utilized primarily in the characterization and quantification of drug purity in pharmaceutical formulations. Its presence may affect the pharmacological profile and efficacy of Ribociclib, making it an important compound for quality control and regulatory compliance in drug development and research applications. -
Drug Impurity
Vitamin Impurity 4 is a chemical impurity associated with vitamin compounds, primarily impacting drug safety and efficacy evaluation. This reagent is commonly utilized in quality control assessments within pharmaceutical research, helping to ensure compliance with regulatory standards. Its role as an impurity provides crucial insights into the stability and purity of vitamin formulations, making it an essential tool for researchers involved in vitamin-related studies. -
Drug Impurity
Rebamipide impurity 6 is a known impurity associated with Rebamipide, a therapeutic agent primarily targeting mucosal protection in gastrointestinal disorders. This compound is essential for analytical studies and quality control processes in pharmaceutical research. Its identification and characterization aid in understanding the compound's stability and efficacy profiles. -
Drug Impurity
Vonoprazan impurity 6 is a chemical impurity associated with Vonoprazan, a proton pump inhibitor. It serves as an important reference standard for analytical and quality control purposes in the pharmaceutical industry. The characterization of this impurity aids in ensuring the purity and safety of Vonoprazan formulations, contributing to the rigorous standards of drug development and regulatory compliance. -
Drug Impurity
(S)-Ponesimod is a chiral impurity associated with the selective S1P receptor modulator, Ponesimod. Its presence is relevant in the development and quality control of therapeutic formulations targeting autoimmune diseases. Research applications include assessing drug purity and understanding the pharmacokinetics of S1P receptor modulators. -
Drug Impurity
Quetiapine impurity 25 is a drug impurity related to Quetiapine, an atypical antipsychotic. This impurity may be utilized in the evaluation of the quality and efficacy of pharmaceutical formulations containing Quetiapine. Its characterization is essential for ensuring compliance with regulatory standards and for understanding the metabolic pathways and potential side effects associated with Quetiapine use in clinical settings. -
Methamphetamine Impurity
N-Formylmethamphetamine is identified as an impurity in the synthesis of methamphetamine and serves as a by-product of the Nagai reaction. Its characterization is essential for assessing the purity of methamphetamine samples in research settings. This compound aids in studies focused on understanding synthesis pathways and enhancing analytical methods in forensic toxicology. -
SM-102 Impurity
SM-102 N-Oxide is a structural impurity of the lipophilic compound SM-102. As an important byproduct in lipid-based research, it is utilized primarily to investigate the biophysical properties and efficacy of lipid formulations. Its presence can influence the performance characteristics in applications such as gene delivery and RNA therapeutics. -
Drug Impurity
Rebamipide impurity 1 is a chemical impurity associated with Rebamipide, a gastroprotective agent. This impurity is crucial for analytical and quality control purposes in the evaluation of drug purity and formulation. Researchers can utilize this compound to assess the integrity and stability of Rebamipide in various biological studies and formulations. -
Drug Impurity
Apixaban impurity 28 is a chemical impurity associated with the anticoagulant agent Apixaban. This compound serves as a reference standard for analytical characterization and quality control of Apixaban formulations. Its identification and quantification are critical for ensuring the integrity and safety of pharmaceutical products containing Apixaban, making it valuable for research and development in drug formulation and regulatory compliance. -
Drug Impurity
Ribociclib impurity 1 is a known impurity associated with the CDK4/6 inhibitor Ribociclib. This compound serves as a reference standard for quality control and characterization of Ribociclib formulations. It is essential in analytical applications to ensure the purity and efficacy of ribociclib in pharmaceutical development and research. -
Drug Impurity
Leflunomide impurity 2, also known as 4-Aminobenzotrifluoride, is identified as a drug impurity associated with Leflunomide. This compound may serve as a valuable reference standard for analytical methods aimed at evaluating the purity of Leflunomide formulations, contributing to quality control measures in pharmaceutical research. Its role in drug development underscores the importance of understanding and characterizing potential impurities in therapeutic agents. -
Drug Impurity
Apixaban impurity 2 is a characterized impurity of the anticoagulant Apixaban. Its analysis is critical for assessing the purity and quality of Apixaban formulations. This impurity is useful in regulatory and stability studies, as well as in the development of analytical methods for drug characterization and quality control in pharmaceutical research. -
Drug Impurity
Ondansetron impurity 7 (2-Methyl-1H-imidazole) is a known impurity in the synthesis of Ondansetron. This compound serves as a reference standard for analytical chemistry and quality control processes in pharmaceutical research. It is primarily utilized for assessing the purity of Ondansetron formulations and for studying potential effects associated with impurities in drug development.
